RoACTEMRA(Tocilizumab) use in patients with early Rheumatoid Arthritis has been approved by European Commission .This drug is an anti-interlukin6 (IL-6) receptor antagonist monoclonal antibody. Roche and Chugai Pharmaceuticals co developed the RoACTERMA(Tocilizumab).
European Commission approved Tocilizumab based on data from the phase 3 function studies which evaluated safety ,efficacy and prevention of joint damage in Early Rheumatoid Arthritis patients.
After 24 weeks of treatment as a monotherapy or in combination with Methotrexate(Popular anti cancer drug ) ,this drug(RoACTEMRA) met its primary end point where there is more significant improvement in RA patients as compared to Methotrexate alone.
Chemical formula of Tocilizumab: C6428H9976N1726O2018S42
Mechanism of Action : Tocilizumab binds specifically to membrane bound and soluble Interlukin 6 receptors, mIL6 & sIL6 and inhibits IL-6 mediated signalling through receptors.
Adverse effects of Tocilizumab : Respiratory tract infections,hypertension, headache,and nasopharyngitis
European Commission approved Tocilizumab based on data from the phase 3 function studies which evaluated safety ,efficacy and prevention of joint damage in Early Rheumatoid Arthritis patients.
After 24 weeks of treatment as a monotherapy or in combination with Methotrexate(Popular anti cancer drug ) ,this drug(RoACTEMRA) met its primary end point where there is more significant improvement in RA patients as compared to Methotrexate alone.
Chemical formula of Tocilizumab: C6428H9976N1726O2018S42
Mechanism of Action : Tocilizumab binds specifically to membrane bound and soluble Interlukin 6 receptors, mIL6 & sIL6 and inhibits IL-6 mediated signalling through receptors.
Adverse effects of Tocilizumab : Respiratory tract infections,hypertension, headache,and nasopharyngitis